Trials / Unknown
UnknownNCT05114759
A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
A Phase I, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A2009 for Injection in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A2009 | In dose Escalation: SHR-A2009 will be administered intravenously. Six dose levels are preset. In dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage. In indication Expansion: Indications will be selected to evaluate preliminary efficacy. |
Timeline
- Start date
- 2022-01-04
- Primary completion
- 2023-12-30
- Completion
- 2024-12-30
- First posted
- 2021-11-10
- Last updated
- 2022-10-12
Locations
16 sites across 3 countries: China, Japan, South Korea
Source: ClinicalTrials.gov record NCT05114759. Inclusion in this directory is not an endorsement.